| scholarly article | Q13442814 |
| P50 | author | Arnab Ghosh | Q63544104 |
| P2093 | author name string | Miguel-Angel Perales | |
| Ioannis Politikos | |||
| P2860 | cites work | Restoring antitumor immunity via PD-1 blockade after autologous stem-cell transplantation for diffuse large B-cell lymphoma | Q86532051 |
| IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells | Q24546362 | ||
| Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens | Q24644442 | ||
| Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors | Q24647124 | ||
| Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting | Q26742012 | ||
| Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation. | Q27691802 | ||
| The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation | Q28066941 | ||
| CAR therapy: the CD19 paradigm | Q28081642 | ||
| Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion | Q28281101 | ||
| Chimeric antigen receptor T cells for sustained remissions in leukemia | Q29617588 | ||
| Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia | Q29617590 | ||
| T cell exhaustion | Q29620463 | ||
| CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia | Q29620607 | ||
| PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma | Q29620878 | ||
| Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. | Q33632062 | ||
| Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma | Q33738783 | ||
| Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin's lymphoma with an emphasis on targeted therapies and transplantation strategies | Q33886267 | ||
| The Basic Principles of Chimeric Antigen Receptor Design | Q34036213 | ||
| Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor | Q34041792 | ||
| Reduced mortality after allogeneic hematopoietic-cell transplantation | Q34472861 | ||
| PD-L1 blockade effectively restores strong graft-versus-leukemia effects without graft-versus-host disease after delayed adoptive transfer of T-cell receptor gene-engineered allogeneic CD8+ T cells | Q34557896 | ||
| Adoptive transfer of T-cell precursors enhances T-cell reconstitution after allogeneic hematopoietic stem cell transplantation | Q34561047 | ||
| PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. | Q34587249 | ||
| Donor lymphocyte infusion: the use of alloreactive and tumor-reactive lymphocytes for immunotherapy of malignant and nonmalignant diseases in conjunction with allogeneic stem cell transplantation | Q34619745 | ||
| Enhanced responses to tumor immunization following total body irradiation are time-dependent | Q35070312 | ||
| Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go? | Q35594089 | ||
| 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors | Q35690389 | ||
| Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease | Q35904666 | ||
| Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study | Q36043066 | ||
| Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans | Q36060239 | ||
| Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors | Q36070000 | ||
| Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia | Q36110355 | ||
| The many faces of IL-7: from lymphopoiesis to peripheral T cell maintenance | Q36133008 | ||
| Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. | Q36253967 | ||
| T cell immune reconstitution following lymphodepletion. | Q36334023 | ||
| Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma | Q36356089 | ||
| Pathophysiology of graft-versus-host disease | Q36368101 | ||
| T-cell Exhaustion in Multiple Myeloma Relapse after Autotransplant: Optimal Timing of Immunotherapy | Q36436758 | ||
| Hematopoietic stem-cell transplantation | Q36461248 | ||
| Murine allogeneic CD19 CAR T cells harbor potent antileukemic activity but have the potential to mediate lethal GVHD. | Q36675086 | ||
| Relapse after allogeneic hematopoietic cell therapy. | Q36799799 | ||
| CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients | Q36951727 | ||
| Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation | Q37008223 | ||
| Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL. | Q37015682 | ||
| CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation | Q37100764 | ||
| CD34-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Relapsed, High-Risk Multiple Myeloma | Q37155605 | ||
| Donor T cells primed on leukemia lysate-pulsed recipient APCs mediate strong graft-versus-leukemia effects across MHC barriers in full chimeras. | Q37176587 | ||
| Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study | Q37263151 | ||
| Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation | Q37390239 | ||
| Genetically engineered donor T cells to optimize graft-versus-tumor effects across MHC barriers | Q37416883 | ||
| Programmed Death Receptor-1/Programmed Death Receptor Ligand-1 Blockade after Transient Lymphodepletion To Treat Myeloma | Q37478912 | ||
| Ipilimumab for Patients with Relapse after Allogeneic Transplantation. | Q37491836 | ||
| The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of follicular lymphoma: an evidence-based review | Q37683993 | ||
| Antibody-modified T cells: CARs take the front seat for hematologic malignancies | Q37723469 | ||
| The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large B cell lymphoma: update of the 2001 evidence-based review | Q37775294 | ||
| Targeting the bone marrow microenvironment in multiple myeloma. | Q38289041 | ||
| Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: guidelines from the American Society for Blood and Marrow Transplantation. | Q38378907 | ||
| Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. | Q38386440 | ||
| Immune checkpoint blockade in hematologic malignancies | Q38400922 | ||
| Fast Cars and No Brakes: Autologous Stem Cell Transplantation as a Platform for Novel Immunotherapies | Q38612233 | ||
| Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma. | Q38793719 | ||
| Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma | Q38837680 | ||
| Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. | Q38852886 | ||
| PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma | Q38868430 | ||
| Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma | Q38874291 | ||
| Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial | Q38906747 | ||
| Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells | Q38945853 | ||
| PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas | Q38996724 | ||
| Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel | Q39092515 | ||
| Hematopoietic stem cell transplantation and cellular therapy | Q39216720 | ||
| Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma | Q39308923 | ||
| Programmed Death Ligand 1 Is Expressed by Non–Hodgkin Lymphomas and Inhibits the Activity of Tumor-Associated T Cells | Q39548715 | ||
| The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody | Q39705098 | ||
| Multiple myeloma causes clonal T-cell immunosenescence: identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade. | Q39832619 | ||
| T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial | Q40186710 | ||
| PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. | Q40216708 | ||
| Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma. | Q40303771 | ||
| PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase. | Q40336693 | ||
| Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. | Q40386808 | ||
| Generation of Genetically Engineered Precursor T-Cells From Human Umbilical Cord Blood Using an Optimized Alpharetroviral Vector Platform | Q40772331 | ||
| PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome | Q41069147 | ||
| Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity. | Q41131801 | ||
| Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma | Q41719867 | ||
| PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies | Q41826795 | ||
| PD-L1 interacts with CD80 to regulate graft-versus-leukemia activity of donor CD8+ T cells | Q42256164 | ||
| Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study | Q43889424 | ||
| Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma | Q48210674 | ||
| Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure | Q49211560 | ||
| PD-1 Blockade in Mediastinal Gray-Zone Lymphoma. | Q49872486 | ||
| PD-1/PD-L1 interactions contribute to functional T-cell impairment in patients who relapse with cancer after allogeneic stem cell transplantation | Q51005275 | ||
| Myeloma Drug Resistance Induced by Binding of Myeloma B7-H1 (PD-L1) to PD-1. | Q51627745 | ||
| Nivolumab salvage therapy before or after allogeneic stem cell transplantation in Hodgkin lymphoma | Q52777496 | ||
| Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. | Q55043619 | ||
| Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma | Q58415969 | ||
| PD-1 checkpoint blockade in patients with relapsed AML after allogeneic stem cell transplantation | Q59678785 | ||
| Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients | Q68640720 | ||
| Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation | Q73117300 | ||
| Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation | Q77145697 | ||
| P433 | issue | 6 | |
| P304 | page(s) | 474-483 | |
| P577 | publication date | 2017-09-01 | |
| P1433 | published in | Current Opinion in Oncology | Q1909046 |
| P1476 | title | Stop and go: hematopoietic cell transplantation in the era of chimeric antigen receptor T cells and checkpoint inhibitors | |
| P478 | volume | 29 |
| Q47443955 | Building a Safer and Faster CAR: Seatbelts, Airbags, and CRISPR. |
| Q90065724 | Early experience using salvage radiotherapy for relapsed/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy |
| Q98223086 | Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors |
| Q52668511 | Severe pembrolizumab-associated neutropenia after CD34+ selected allogeneic hematopoietic-cell transplantation for multiple myeloma. |
Search more.